MA26771A1 - Benzoheterocycles et leur utilisation comme inhibiteurs de mek. - Google Patents

Benzoheterocycles et leur utilisation comme inhibiteurs de mek.

Info

Publication number
MA26771A1
MA26771A1 MA26293A MA26293A MA26771A1 MA 26771 A1 MA26771 A1 MA 26771A1 MA 26293 A MA26293 A MA 26293A MA 26293 A MA26293 A MA 26293A MA 26771 A1 MA26771 A1 MA 26771A1
Authority
MA
Morocco
Prior art keywords
benzoheterocycles
mek inhibitors
mek
inhibitors
Prior art date
Application number
MA26293A
Other languages
English (en)
Inventor
Douglas Barrett Stephen
Tecle Haile
James Bridges Alexander
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA26771A1 publication Critical patent/MA26771A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
MA26293A 1999-01-13 2001-08-10 Benzoheterocycles et leur utilisation comme inhibiteurs de mek. MA26771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11587399P 1999-01-13 1999-01-13
US12255399P 1999-03-02 1999-03-02

Publications (1)

Publication Number Publication Date
MA26771A1 true MA26771A1 (fr) 2004-12-20

Family

ID=26813662

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26293A MA26771A1 (fr) 1999-01-13 2001-08-10 Benzoheterocycles et leur utilisation comme inhibiteurs de mek.

Country Status (31)

Country Link
US (1) US6469004B1 (fr)
EP (1) EP1144385B1 (fr)
JP (1) JP4621355B2 (fr)
KR (1) KR20020002370A (fr)
CN (1) CN1177830C (fr)
AP (1) AP2001002224A0 (fr)
AT (1) ATE302193T1 (fr)
AU (1) AU2203700A (fr)
BG (1) BG105800A (fr)
BR (1) BR9916904A (fr)
CA (1) CA2355470C (fr)
CZ (1) CZ20012498A3 (fr)
DE (1) DE69926800T2 (fr)
EA (1) EA200100772A1 (fr)
EE (1) EE200100373A (fr)
ES (1) ES2247859T3 (fr)
GE (1) GEP20032922B (fr)
HK (1) HK1041697A1 (fr)
HR (1) HRP20010524A2 (fr)
HU (1) HUP0105113A3 (fr)
ID (1) ID30439A (fr)
IL (1) IL144214A0 (fr)
IS (1) IS5976A (fr)
MA (1) MA26771A1 (fr)
NO (1) NO20013452L (fr)
NZ (1) NZ513433A (fr)
OA (1) OA11746A (fr)
SK (1) SK9832001A3 (fr)
TR (1) TR200102030T2 (fr)
WO (1) WO2000042022A1 (fr)
YU (1) YU49401A (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350234A1 (fr) * 1999-01-07 2000-07-13 Alexander James Bridges Traitement de l'asthme a l'aide d'inhibiteurs de mek
IL147150A0 (en) * 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
AU7349801A (en) * 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (fr) * 2002-03-13 2003-09-25 Array Biopharma, Inc Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
CA2532067C (fr) 2003-07-24 2010-12-21 Stephen Douglas Barrett Benzimidazoles n-methyle-substitues
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
KR101013932B1 (ko) * 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
CN1902193B (zh) 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CA2583096A1 (fr) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines en tant qu'inhibiteurs b-raf
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
KR101357361B1 (ko) 2005-06-23 2014-02-03 아스트라제네카 아베 벤즈이미다졸 화합물의 ＳｎＡｒ 제조 방법
EP1904481B1 (fr) 2005-06-23 2016-02-17 Array Biopharma, Inc. Procede d'elaboration de composes benzimidazole
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
WO2008006039A1 (fr) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothiéno pyrimidines comme inhibiteurs de la protéine kinase akt
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
WO2008024724A1 (fr) * 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
RU2444524C2 (ru) * 2006-08-21 2012-03-10 Дженентек, Инк. Азабензотиофенильные соединения и способы применения
CA2660546A1 (fr) * 2006-08-21 2008-02-28 Genentech, Inc. Composes aza-benzofuranyle et leurs procedes d'utilisation
WO2008076415A1 (fr) 2006-12-14 2008-06-26 Exelixis, Inc. Procédés d'utilisation d'inhibiteurs de mek
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20080312307A1 (en) * 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
MX2009014013A (es) 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692502C (fr) 2007-07-05 2016-03-01 Array Biopharma Inc. Cyclopentanes de pyrimidyle comme inhibiteurs de proteines kinases akt
TWI441820B (zh) * 2007-12-19 2014-06-21 Genentech Inc ５－苯胺咪唑并吡啶及使用方法
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
AU2009279940B2 (en) 2008-08-04 2014-01-16 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
EP2346818B1 (fr) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Sulfonamido phénoxybenzamides substitués
EP2370568B1 (fr) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mutations de mek conférant une résistance aux inhibiteurs de mek
CA2777430A1 (fr) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitues
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2789696C (fr) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Mutations de braf conferant une resistance aux inhibiteurs de braf
EP2545187B1 (fr) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Procédés de diagnostic et de traitement du cancer chez des patients ayant ou développant une résistance à une première thérapie anticancéreuse
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012055953A1 (fr) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Phénoxypyridines substituées
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
EP2714037B1 (fr) 2011-05-25 2016-07-13 Université Paris Descartes Inhibiteurs de la voie erk pour le traitement de l'amyotrophie spinale
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
CN103204825B (zh) * 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
WO2013169858A1 (fr) 2012-05-08 2013-11-14 The Broad Institute, Inc. Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse
EP2854779A1 (fr) 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarqueurs pour la détermination de la réponse efficace de traitements de patients atteints d'un carcinome hépatocellulaire (hcc)
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
CA3079071C (fr) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation de derive benzimidazole cristallise comme inhibiteur mek et formulation la comprenant
WO2015038704A1 (fr) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions pour prépaprer des cardiomyocytes
WO2015108907A2 (fr) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
CN104774188B (zh) * 2014-01-15 2019-10-11 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
BR112018012255A2 (pt) * 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN114478447B (zh) * 2020-11-13 2024-12-13 江苏恒瑞医药股份有限公司 苯并含氧环类衍生物、其制备方法及其在医药上的应用
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
EP4788839A1 (fr) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン

Also Published As

Publication number Publication date
OA11746A (en) 2005-05-13
HUP0105113A3 (en) 2004-11-29
TR200102030T2 (tr) 2002-01-21
EP1144385A1 (fr) 2001-10-17
EA200100772A1 (ru) 2002-02-28
JP2002534510A (ja) 2002-10-15
WO2000042022A1 (fr) 2000-07-20
CN1333754A (zh) 2002-01-30
SK9832001A3 (en) 2003-02-04
HUP0105113A2 (hu) 2002-04-29
IL144214A0 (en) 2002-05-23
NO20013452D0 (no) 2001-07-12
EE200100373A (et) 2002-10-15
DE69926800D1 (de) 2005-09-22
ID30439A (id) 2001-12-06
CA2355470C (fr) 2008-09-30
HRP20010524A2 (en) 2002-08-31
CA2355470A1 (fr) 2000-07-20
US6469004B1 (en) 2002-10-22
DE69926800T2 (de) 2006-05-18
ES2247859T3 (es) 2006-03-01
YU49401A (sh) 2004-07-15
JP4621355B2 (ja) 2011-01-26
NO20013452L (no) 2001-07-12
CN1177830C (zh) 2004-12-01
HK1041697A1 (zh) 2002-07-19
EP1144385B1 (fr) 2005-08-17
ATE302193T1 (de) 2005-09-15
KR20020002370A (ko) 2002-01-09
CZ20012498A3 (cs) 2002-08-14
AP2001002224A0 (en) 2001-09-30
IS5976A (is) 2001-06-22
GEP20032922B (en) 2003-03-25
AU2203700A (en) 2000-08-01
BG105800A (en) 2002-03-29
NZ513433A (en) 2003-05-30
BR9916904A (pt) 2001-10-30

Similar Documents

Publication Publication Date Title
MA25688A1 (fr) 2-thio-3, 5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation.
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
NO20005359L (no) Kombinert lager- og driftsystem
MA26348A1 (fr) 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
MA24237A1 (fr) Sulfonamides et leur utilisation.
FR12C0019I2 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
DE60019903D1 (de) Speichersystem
BR0014932B1 (pt) conjunto de retenção.
DK1181269T3 (da) Celleproliferationsinhibitorer
FI980614A0 (fi) Pao funktionstillstaond beroende svaromeddelande
EP1210084A4 (fr) Pyridomorphinanes, thienomorphinanes et utilisation
DE50012719D1 (de) Holster
PT1214302E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase
DE50001726D1 (de) Batteriesystem
MA25814A1 (fr) Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase.
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
EP1139913A4 (fr) Composition et formulations et leur utilisation comme nociceptifs, anti-anxiolytiques et anabolisants
LU90463B1 (de) Etagenofen
FR2798017B1 (fr) Dephaseur, et demodulateur utilisant ce dephaseur
IT1307028B1 (it) Bendaggio.
ES1046207Y (es) Corrector de gesticulacion antiarrugas y antiojeras.
MA25815A1 (fr) Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase.
DE10082148D2 (de) Computersystem
DK199900591A (da) Våbensystem
NO995103D0 (no) Tappekniven